GI Innovation affiliate GI Biome announced on the 21st that it has signed a memorandum of understanding (MOU) for the development of decentralized clinical trial (DCT) business and global market entry with AI smart watch-based medication management solution company InHandPlus and digital healthcare service platform company GI Vita.
Lee Hwi-won, CEO of InHandPlus, Lee Gil-yeon, CEO of GIBITA, and Kim Young-seok, CEO of GI Biome (from left), are posing for a commemorative photo at the "Memorandum of Understanding Signing Ceremony for Joint Research and Business Development of Decentralized Clinical Trials." Photo by GI Biome
Through this agreement, the three companies plan to introduce a medication monitoring system and personalized medication management services using smart devices into clinical trials, and promote the development of an optimized DCT platform and global commercialization.
GI Biome is developing microbiome new drugs for the treatment of cancer, metabolic diseases, and allergic diseases. The anticancer microbiome therapeutic candidate 'GB-X01' began dosing the first patient in Phase 1 clinical trials this month. During the Phase 1 trial design process, the company recognized the importance of managing patient medication adherence and collaborated with InHandPlus, which possesses technology to monitor medication behavior through wearable devices. Kim Young-seok, CEO of GI Biome, said, “Since the COVID-19 pandemic, DCT has been gaining ground as a mainstream approach, especially in major advanced countries. Through this MOU, we want to present a DCT model that leads global trends.”
InHandPlus enables monitoring of when and what medication users take through AI smart watch-based medication behavior analysis technology. Based on this, it provides automatic remote collection of real-world medication adherence data (RWD) and personalized medication management services. Lee Hwi-won, CEO of InHandPlus, stated, “Not only medication data but also various health lifestyle records such as activity level, heart rate, and sleep status can be analyzed, making it optimal for remote patient monitoring. We will create great synergy in the global DCT business through cooperation with GI Biome and GI Vita.”
GI Vita is a digital healthcare platform company that provides health management and disease prevention solutions through health data AI technology and guidance from medical experts. Through this MOU, it plans to develop demonstration business models and advance solutions for the commercialization of the DCT model.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
